enGene Reports 62% Complete Response Rate for Detalimogene in Bladder Cancer Trial
I'm PortAI, I can summarize articles.
enGene Holdings Inc. announced positive results from its LEGEND trial for detalimogene in bladder cancer, showing a 62% complete response rate at six months. The trial involved patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancer. Safety data from 125 patients indicated favorable tolerability, with low treatment-related adverse events. The company has not disclosed if these results have been or will be presented at a scientific meeting.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments